RESUMO
An open label study was conducted to asses the efficacy and safety of rosiglitazone when administered concurrently with sulphonylurea compounds. Sixty-three type 2 diabetic patients were enrolled in the study in three different centres across Nigeria, Zaria in the north, Lagos in the southwest and Port Harcourt in the southeast. Nigeria is a large country with multiethnic groups. Subjects were randomly divided into two treatment groups; one on only sulphonylurea and the other on rosiglitazone [4 mg daily] for 26 weeks in addition to the current dose of sulphonylurea. Fifty-two subjects [82.5%] completed the study. The addition of rosiglitazone to sulphonylurea therapy resulted in more steady control of fasting plasma glucose [FPG] over time, higher mean change in FPG from baseline and higher proportion of subjects recording HBA1C value of